BRAF and colorectal carcinoma: CDX2 is absent in around 10% of CRC cancers [130], and CDX2-negative tumours are often associated with several adverse prognostic features, such as advanced stage, vascular invasion, poor differentiation, right-sided location, CIMP, and BRAF mutation [128,131].